1. Benner J, Glynn R, Mogun H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderley patients. JAMA 2002;288:455-61.
2. Morrison A, Wertheimer A, Berger M. Interventions to improve antihypertensive drug adherence: A quantitative review of trials. Formulary 2000;35:234-55.
3. World Health Organisation. Adherence to long-term therapies. Evidence for Action. Geneva: WHO, 2003.
4. McDonald H, Garg A, Haynes R. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79.
5. Maggiolo F, Ripimonti D, Arici C, Gregis G, Quinzan G, Camacho G, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials 2002;3:371-8.
6. Murray M, Birt J, Manatunga A, JC D. Medication compliance in elderly outpatients using twice daily dosing and unit-of-use packaging. Ann Pharmacother 1993;27(616-21).
7. Paes A, Bakker A, Soe-Agnie C. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.
8. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settingns: treatment guidelines for a public health approach. Geneva: WHO, 2003.
9. Silveira Vl, Pinheiro CAT, Drachler ML, Leite JCC. Adherence to antiretroviral therapy and characteristics of treatment regimens among HIV-infected patients. (abstract) 2nd IAS Conference on HIV pathogenesis and treatment; 2003; Paris.
10. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Under review at BWHO 2003.
11. Su W, Perng R. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002;6:1029-32.
12. Geiter L, O'Brien R, Combs D, Snider D. United States Public Health Service Tuberculosis Therapy Trial 21: Preliminary results of an evaluation of a combination tablet of isoniazid, rifampicin and pyrazinamide. Tubercle 1987;68:41-6.
13. Eron J, Yetzer E, Ruane P, Becker S, Sawyerr G, Fisher R, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000;14:671-81.
14. Revankar C, Nivedita G, Sorensen B, Naik S. Further observations on MDT blister-calendar packs in vertical leprosy eradication programmes a -multicentre study (Phase II). Lepr Rev 1993;64:250-4.
15. Yeboah-Antwi K, Gyapong J, Asare I, Barnish G, Evans D, Adjei S. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bulletin of the World Health Organisation 2001;79:394-9.
16. Simmons D, Upjohn M, Gamble G. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care 2000;23(2):153-6.
17. Binstock M, Franklin K. A comparison of compliance techniques on the control of high blood pressure. AJH 1988;1:192S-194S.
18. Becker L, Glanz K, Sobel E, Mossey J, Zinn S, Andrews Knott K. A randomized trial of special packaging of antihypertensive medications. J Fam Pract 1986;22:357-361.
19. Rehder T, McCoy L, Blackwell B, Whitehead W, Robinson A. Improving medication compliance by counseling and special prescription container. Am J Hosp Pharm 1980;37(379-85).
20. Ware G, Holford N, Davison J. Unit dose dispensing. NZ Med J 1991;104:495-7.
21. Wong B, Norman D. Evaluation of a novel medication aid, the calendar blister-pak, and its effect on drug compliance in a geriatric outpatient clinic. J Am Geriatric Soc 1987;35:21-26.
22. Crome P, Akehurst M, Keet J. Drug compliance in elderly hospital in-patients: Trial of the Dosett box. The Practitioner 1980;224:782-5.
23. Crome P, Curl B, Boswell M, Corless D, Lewis R. Assessment of a new calendar pack the - C - Pak. Age Ageing 1982;11:275-9.
24. Haynes R, McKibbon K, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;348:383-6.
25. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampicin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991;143:707-12.
26. Teo S. Assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide (Ritafer) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999;3:126-32.
27. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampicin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Respir Dis 1989;140:1618-22.
28. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 montyhs of pyrazinamide in pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Am Rev Respir Dis 1991;143:700-6.
29. Zhang L. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Current Therapeutic Research 1996;57:849-856.
30. Qingjun L, Jihui D, Laiyi T, Xiangjun Z, Jun L, Hay A, et al. The effect of drug packaging on patients compliance with treatment for plasmodium vivax malaria in China. Bulletin of the World Health Organisation 1998;76(Suppl 1):21-7.
31. Shwe T, Lwin M, Aung S. Influence of blister packaging on the efficacy of artesunate and mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar. Bulletin of the World Health Organisation 1998;76(Suppl 1):35-41.
32. Ibarra I, Martinez-Bengoechea MJ, Peral J, Santos A, Illaro A, Lertxundi U et al. Assessing adherence in a treatment simplification. (abstract) 2nd IAS Conference on HIV pathogenesis and treatment; 2003; Paris.
33. Barigye H, Luyirika E. The challenges of paediatric ARV formulations in resource-poor countries the - Ugandan experience. (abstract) 2nd IAS Conference on HIV pathogenesis and treatment; 2003; Paris.
34. Rozenbaum W, Chauveau E. Phase 3 study of the antiviral activity of AZT + 3TC given as separate regimens versus a new fixed-dose combination (abstract 669). The 5th Conference on Retroviruses and Opportunistic Infections; 1998; Chicago.